NCT05630196已完成2 期
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3857210 for the Treatment of Chronic Low Back Pain
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 138
- 试验地点
- 28
- 主要终点
- Change From Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)
研究概览
简要总结
The main purpose of this study is to assess whether LY3857210 is safe and efficacious in relieving chronic low back pain (CLBP). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292), which is a protocol to accelerate the development of new treatments for chronic pain.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have a visual analog scale (VAS) pain value ≥40 and <95 during screening.
- •Have a history of daily pain for at least 12 weeks based on participant report or medical history.
- •Have a body mass index <40 kilograms per meter squared (kg/m²) (inclusive).
- •Are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain-relieving therapies (for example, physical therapy) and will not start any new nonpharmacologic pain-relieving therapies during study participation.
- •Are willing to discontinue all medications taken for chronic pain conditions for the duration of the study.
- •Have a history of low back pain for at least 3 months located between the 12th thoracic vertebra and the lower gluteal folds, with or without radiation.
- •Have a history of low back pain as classified by the Quebec Task Force Category 1 through
- •Have stable glycemic control as indicated by a glycated hemoglobin (HbA1c) less than or equal to 10 at time of screening.
- •Are men, or women able to abide by reproductive and contraceptive requirements.
排除标准
- •Have a seizure disorder, history of seizure (other than remote history of childhood febrile seizure), or a condition that would place the participant at increased risk of seizure, such as head injury (for example, skull fracture, cerebral contusion, concussion, or trauma resulting in prolonged unconsciousness), intracranial neoplasm or hemorrhage.
- •Have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest (for example, ablation techniques).
- •Have surgery planned during the study for any reason, related or not to the disease state under evaluation.
- •Have, in the judgment of the investigator, an acute, serious, or unstable medical condition or a history or presence of any other medical illness that would preclude study participation.
- •Have had cancer within 2 years of baseline, except for cutaneous basal cell or squamous cell carcinoma resolved by excision.
- •Have a substance use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (5th edition; DSM-5; American Psychiatric Association).
- •Have a positive human immunodeficiency virus (HIV) test result at screening.
- •Are, in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide.
- •Have an intolerance to acetaminophen or paracetamol or any of its excipients.
- •Have a history of alcohol, illicit drug, analgesic or narcotic use disorder within 2 years prior to screening.
- •Have used a therapeutic injection (botulinum toxin or corticosteroids) in the 3 months prior to starting the washout period.
- •Have history of or current compression fracture.
- •Have had a recent major trauma (within 6 months of baseline).
- •Are pregnant or breastfeeding.
- •Have known history of gastric or duodenal ulcers.
- •Have known history of inflammatory bowel disease (including ulcerative colitis or Crohn's disease).
研究组 & 干预措施
LY3857210
Experimental
Participants received 45 milligrams (mg) of LY3857210 orally once daily for up to 8 weeks.
干预措施: LY3857210 (Drug)
Placebo
Placebo Comparator
Participants received placebo orally once daily for up to 8 weeks.
干预措施: Placebo (Drug)
结局指标
主要结局
Change From Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)
时间窗: Baseline, Week 8
The NRS was used to describe pain severity. Participants were asked to describe their average pain over the past 24 hours, on a scale of 0 to 10: 0 = no pain, and 10 = pain as bad as you can imagine. Posterior mean change from baseline, 95 percent (%) credible interval was derived using Bayesian mixed model repeated measures. The data presented are the posterior mean with a 95% credible interval.
次要结局
- Change From Baseline for Worst Pain Intensity as Measured by NRS(Baseline, Week 8)
- Change From Baseline on the Visual Analog Scale (VAS) for Pain(Baseline, Week 8)
- Change From Baseline on the Sleep Scale From the Medical Outcomes Study (MOS Sleep Scale) - Average Hours of Sleep(Baseline, Week 8)
- Change From Baseline on the Roland Morris Disability Questionnaire (RMDQ)(Baseline, Week 8)
- Mean Overall Improvement as Measured by Patient's Global Impression of Change(Week 8)
- Total Amount of Rescue Medication Use as Measured by Average Daily Dosage(Week 8)
- Change From Baseline on the EuroQuality of Life Five Dimensions (5D) Five Level (5L) Questionnaire (EQ-5D-5L) Health State Index (United States Algorithm)(Baseline, Week 8)
研究者
研究点 (28)
Loading locations...
相似试验
已完成
2 期
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 In Participants With Osteoarthritis PainOsteoarthritisNCT05620563Eli Lilly and Company147
已完成
2 期
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).Diabetic Peripheral Neuropathic PainNCT05620576Eli Lilly and Company131
已完成
2 期
Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic PainDiabetic Peripheral Neuropathic PainNCT05177094Eli Lilly and Company155
已完成
2 期
Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Chronic Low Back PainChronic Low-back PainNCT05086289Eli Lilly and Company159
已完成
2 期
Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With OsteoarthritisOsteo Arthritis KneeOsteoarthritisNCT05080660Eli Lilly and Company160